Category: Healthcare & Pharmaceuticals

Clinical Trials Healthcare & Pharmaceuticals News

Lilly’s Retevmo Shows Substantial Survival Benefit in Early-Stage Lung Cancer Trial

Eli Lilly and Company

Eli Lilly’s Retevmo (selpercatinib) has shown promising results as an adjuvant therapy for early-stage lung cancer. The Phase 3 LIBRETTO-432 trial revealed that Retevmo adjuvant therapy significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer (NSCLC), marking a breakthrough for this rare molecular subtype affecting 1-2% of lung cancer cases.

Regulatory Approval Autoimmune Diseases News

Amgen Wins EU Approval for UPLIZNA in Rare Muscle-Weakening Disease, Opening New Front in Autoimmune Battle

amgen

The European Commission has granted approval for Amgen’s UPLIZNA® (inebilizumab) as an add-on treatment for adults with generalized myasthenia gravis making it the first and only CD19-targeted therapy authorized in Europe for this rare, debilitating autoimmune muscle disease. The approval is backed by pivotal Phase 3 data from the landmark MINT trial.

Clinical Trials Healthcare & Pharmaceuticals News

AstraZeneca’s Breztri Triple-Therapy Hits Primary Goals in Landmark Phase III Asthma Trials

AstraZeneca

Groundbreaking data from the KALOS and LOGOS trials reveal that Breztri (BGF) triple-therapy significantly outperforms standard dual-combination inhalers for uncontrolled asthma. Published in The Lancet Respiratory Medicine, the study confirms a 76mL improvement in lung function and a meaningful reduction in severe exacerbations, signaling a potential shift in the global standard of care.

Clinical Trials Healthcare & Pharmaceuticals News

Novartis Vanrafia® Phase III Data Show Significant Slowing of Kidney Function Decline in IgA Nephropathy Patients

novartis

Final data from the Phase III ALIGN study reveals that Vanrafia® (atrasentan) effectively slows eGFR decline in IgAN patients, even when combined with SGLT2 inhibitors. Novartis moves toward traditional regulatory approval in 2026.

Business Healthcare & Pharmaceuticals News

AstraZeneca Delivers Robust 2025 Results as $58.7B Revenue as “Blockbuster” Portfolio Expands to 16 Medicines

AstraZeneca

AstraZeneca (AZN) capped off 2025 with a powerhouse performance, reaching $58.74 billion in total revenue and expanding its portfolio to 16 blockbuster drugs. With 100+ Phase III trials ongoing, CEO Pascal Soriot reaffirmed the company’s path to an $80 billion revenue target by 2030.

Business Healthcare & Pharmaceuticals

IQVIA Outpaces Expectations in 2025, Doubles Down on Healthcare-Grade AI Strategy for 2026

iqvia news

Following the release of its IQVIA 2025 earnings, the life sciences leader reported a record-breaking $32.7 billion backlog and a double-digit revenue surge in the fourth quarter, outperforming Wall Street expectations. As the company transitions into 2026, it is doubling down on a specialized Healthcare-grade AI strategy—anchored by its proprietary Med-R1 reasoning model and strategic cloud partnerships with NVIDIA and AWS—to safeguard its core business against industry-wide disruption.

News Healthcare & Pharmaceuticals Regulatory

Pfizer’s HYMPAVZI Receives FDA Priority Review to Expand Treatment to Children and Patients with Hemophilia A or B Without Inhibitors

pfizer news

Pfizer has reached a major regulatory milestone with the FDA granting Priority Review for HYMPAVZI™ (marstacimab) to include children as young as six and patients with hemophilia inhibitors. If approved, HYMPAVZI would become the first non-factor prophylactic treatment for children aged 6–11 with hemophilia B, offering a simplified, once-weekly injection that addresses a massive unmet medical need in the rare disease community.

Business Anti-obesity Drugs Diabetes News

Eli Lilly Released Q4 and 2025 Results; Projects $80B+ Revenue for 2026 as Oral Weight-Loss Drug Orforglipron Nears Approval

Eli Lilly and Company

Eli Lilly (LLY) shattered Q4 2025 expectations with $19.3 billion in revenue, marking a 43% year-over-year increase. Driven by the explosive demand for weight-loss treatments Mounjaro and Zepbound, the pharmaceutical giant issued a confident 2026 revenue guidance of $80B–$83B, signaling continued dominance in the metabolic health market.

Clinical Trials Anti-obesity Drugs News Weight-loss Drugs

Pfizer’s Monthly Obesity Shot Delivers 12% Weight Loss in Milestone Phase 2b Trial

pfizer news

Pfizer’s investigational “ultra-long-acting” GLP-1 receptor agonist, PF-08653944, showed robust 12.3% weight loss in its Phase 2b VESPER-3 study. Transitioning from weekly to a once-monthly injection, the drug maintained high efficacy and tolerability, positioning Pfizer as a major competitor in the 2026 obesity drug market.